Apogee Therapeutics CEO Michael Thomas Henderson sold 20,000 shares (~$1.5 million) on March 11, 2026, representing 1.71% of his holdings. The sale was executed under a Rule 10b5-1 plan, suggesting it reflects a pre-planned strategy rather than negative sentiment. Despite the insider sale, the company's stock has surged nearly 100% in the past year. The article emphasizes that investors should focus on Apogee's positive Phase 2 clinical data showing 85% patient response durability, upcoming Phase 3 trials, and a $350 million equity offering that strengthens its balance sheet for late-stage development.

Apogee Therapeutics priced an underwritten public offering of 5 million shares at $70 per share, raising approximately $350 million in gross proceeds. The offering is expected to close on March 26, 2026. The company is a clinical-stage biotech firm developing novel biologics for inflammatory and immunology markets, with its lead program Zumilokibart (APG777) in development for atopic dermatitis, asthma, and eosinophilic esophagitis.

Apogee Therapeutics announced it will report 52-week Phase 2 APEX trial data for zumilokibart (APG777) in atopic dermatitis patients on March 23, 2026, via conference call at 8:00 a.m. ET. The company is advancing novel biologics targeting inflammatory and immunology markets.

Great Point Partners increased its stake in Apogee Therapeutics (APGE) by 70,000 shares to 374,000 shares worth $28.23 million, making it the fund's largest holding at 9.15% of assets. APGE stock has doubled over the past year and is advancing monoclonal antibody therapies for inflammatory diseases with Phase 2 atopic dermatitis data expected in H1 2026.

Apogee Therapeutics reported positive interim Phase 1b results for zumilokibart (APG777), its anti-IL-13 antibody, in mild-to-moderate asthma patients, demonstrating rapid and durable suppression of FeNO biomarker through 16 weeks with a favorable safety profile. The company also highlighted multiple anticipated 2026 milestones including Phase 2 APEX data readouts in atopic dermatitis and potential Phase 3 initiation by late 2026, with a strong cash position of $913 million supporting operations into H2 2028.

Apogee Therapeutics reported positive Phase 1 trial results for APG333, a novel half-life extended TSLP antibody, demonstrating a 55-day half-life and potential for quarterly dosing in respiratory treatments.

Apogee Therapeutics successfully closed a public offering of 8,048,782 shares and pre-funded warrants, raising approximately $345 million to advance its clinical-stage biologics in inflammatory and immunology markets.

Apogee Therapeutics, a clinical-stage biotech company, announced a secondary stock offering of approximately 6.95 million shares at $41 per share, potentially raising around $300 million for preclinical studies, clinical trials, and research and development activities.

Apogee Therapeutics is conducting a public offering of 6,951,221 common stock shares and pre-funded warrants, expecting to raise approximately $300 million to support its clinical-stage biologics development.

Apogee Therapeutics reported positive 16-week data from its Phase 2 APEX clinical trial of APG777, an anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The trial showed 71% reduction in EASI score and 66.9% of patients achieving EASI-75 response, with a favorable safety profile.

Apogee Therapeutics will report 16-week data from its Phase 2 APEX trial for APG777, a potential treatment for atopic dermatitis, on July 7, 2025, with a conference call and webcast to discuss the results.

Apogee Therapeutics announced positive interim results from a Phase 1b trial of its novel antibody APG808 in patients with mild-to-moderate asthma, showing rapid and sustained suppression of a biomarker of inflammation and a favorable safety profile.